Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 May 16;6(2):38.
doi: 10.3390/diseases6020038.

Pulmonary Arterial Hypertension: Pathophysiology and Treatment

Norris S H Lan  1 , Benjamin D Massam  2 , Sandeep S Kulkarni  3 , Chim C Lang  4
Affiliations
Review

Pulmonary Arterial Hypertension: Pathophysiology and Treatment

Norris S H Lan et al. Diseases. .

Abstract

Pulmonary arterial hypertension (PAH), the first category of pulmonary hypertension, is a chronic and progressive disorder characterised by angioproliferative vasculopathy in the pulmonary arterioles, leading to endothelial and smooth muscle proliferation and dysfunction, inflammation and thrombosis. These changes increase pulmonary vascular resistance and subsequent pulmonary arterial pressure, causing right ventricular failure which leads to eventual death if untreated. The management of PAH has advanced rapidly in recent years due to improved understanding of the condition's pathophysiology, specifically the nitric oxide, prostacyclin-thromboxane and endothelin-1 pathways. Five classes of drugs targeting these pathways are now available: phosphodiesterase-5 inhibitors, soluble guanylate cyclase stimulators, prostacyclin analogues, prostacyclin receptor agonists and endothelin receptor antagonists. These developments have led to substantial improvements in mortality rate in recent decades. Recently, long-term studies have demonstrated sustained progression-free survival and have created a new paradigm of initial combination therapy. Despite these targeted therapies, PAH is still associated with significant morbidity and mortality. As such, further research into broadening our understanding of PAH pathophysiology is underway with potential of increasing the repertoire of drugs available.

Keywords: endothelin receptor antagonists; endothelin-1; mortality; nitric oxide; phosphodiesterase-5 inhibitor; prostacyclin analogues; prostacyclin receptor agonists; prostacyclin-thromboxane; pulmonary arterial hypertension; soluble guanylate cyclase stimulators.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
The key abnormal pathways targeted in the pharmacological treatment of pulmonary arterial hypertension and the mechanism of action for contemporary drugs. The dashed line from ETB denotes action of endothelial ETB activation via NO and PGI2 production. Adapted from Prior et al. MJA 2016 [28].
Figure 2
Figure 2
The European Society of Cardiology and the European Respiratory Society (ESC/ERS) evidence-based treatment algorithm for pulmonary arterial hypertension patients. Adapted from ECS/ERS guidelines for the diagnosis and treatment of pulmonary hypertension [13].
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Hoeper M.M., Bogaard H.J., Condliffe R., Frantz R., Khanna D., Kurzyna M., Langleben D., Manes A., Satoh T., Torres F. Definitions and diagnosis of pulmonary hypertension. J. Am. Coll. Cardiol. 2013;62:D42–D50. doi: 10.1016/j.jacc.2013.10.032. - DOI - PubMed
    1. Moreira E.M., Gall H., Leening M.J., Lahousse L., Loth D.W., Krijthe B.P., Kiefte-de Jong J.C., Brusselle G.G., Hofman A., Stricker B.H. Prevalence of pulmonary hypertension in the general population: The rotterdam study. PLoS ONE. 2015;10:e0130072. doi: 10.1371/journal.pone.0130072. - DOI - PMC - PubMed
    1. Strange G., Playford D., Stewart S., Deague J.A., Nelson H., Kent A., Gabbay E. Pulmonary hypertension: Prevalence and mortality in the armadale echocardiography cohort. Heart. 2012;98:1805–1811. doi: 10.1136/heartjnl-2012-301992. - DOI - PMC - PubMed
    1. Badesch D.B., Raskob G.E., Elliott C.G., Krichman A.M., Farber H.W., Frost A.E., Barst R.J., Benza R.L., Liou T.G., Turner M. Pulmonary arterial hypertension: Baseline characteristics from the reveal registry. Chest. 2010;137:376–387. doi: 10.1378/chest.09-1140. - DOI - PubMed
    1. Tuder R.M., Archer S.L., Dorfmüller P., Erzurum S.C., Guignabert C., Michelakis E., Rabinovitch M., Schermuly R., Stenmark K.R., Morrell N.W. Relevant issues in the pathology and pathobiology of pulmonary hypertension. J. Am. Coll. Cardiol. 2013;62:D4–D12. doi: 10.1016/j.jacc.2013.10.025. - DOI - PMC - PubMed